VCR ventracor limited

funding plan

  1. 177 Posts.
    Good points:
    - BTT trial over 80% complete and due for completion in January. (was supposed to finish end of year but that is good enough)

    Bad points:
    - no cap on bonuses or salaries, especially for director.
    - cessation of R&D (this should not have been compromised)
    - no strategic partnership agreements reached yet

    Overall I'm bullish on VCR and can't believe the price is at this level. Especially when compared to Thoratec capitalisation.

    What I would really like is for VCR to obtain a strategic partnership agreement and continue full steam ahead with R&D. I would definitely partake in SPP then.

 
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.